NDC 50242-082

LUCENTIS

Ranibizumab

LUCENTIS is a Intravitreal Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Genentech, Inc.. The primary component is Ranibizumab.

Product ID50242-082_115f8246-b87c-49aa-b411-e67afecdced9
NDC50242-082
Product TypeHuman Prescription Drug
Proprietary NameLUCENTIS
Generic NameRanibizumab
Dosage FormInjection, Solution
Route of AdministrationINTRAVITREAL
Marketing Start Date2012-08-10
Marketing CategoryBLA / BLA
Application NumberBLA125156
Labeler NameGenentech, Inc.
Substance NameRANIBIZUMAB
Active Ingredient Strength6 mg/mL
Pharm ClassesVascular Endothelial Growth Factor Inhibitors [MoA],Vascular Endothelial Growth Factor Inhibitor [EPC]
NDC Exclude FlagN
Listing Certified Through2020-12-31

Packaging

NDC 50242-082-01

1 VIAL, SINGLE-USE in 1 CARTON (50242-082-01) > .05 mL in 1 VIAL, SINGLE-USE
Marketing Start Date2012-08-10
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 50242-082-02 [50242008202]

LUCENTIS INJECTION, SOLUTION
Marketing CategoryBLA
Application NumberBLA125156
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitML
Marketing Start Date2016-11-28

NDC 50242-082-03 [50242008203]

LUCENTIS INJECTION, SOLUTION
Marketing CategoryBLA
Application NumberBLA125156
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitML
Marketing Start Date2018-03-20

NDC 50242-082-87 [50242008287]

LUCENTIS INJECTION, SOLUTION
Marketing CategoryBLA
Application NumberBLA125156
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitML
Marketing Start Date2017-02-28

NDC 50242-082-88 [50242008288]

LUCENTIS INJECTION, SOLUTION
Marketing CategoryBLA
Application NumberBLA125156
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitML
Marketing Start Date2018-03-20

NDC 50242-082-01 [50242008201]

LUCENTIS INJECTION, SOLUTION
Marketing CategoryBLA
Application NumberBLA125156
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitML
Marketing Start Date2012-08-10

Drug Details

Active Ingredients

IngredientStrength
RANIBIZUMAB6 mg/mL

OpenFDA Data

SPL SET ID:de4e66cc-ca05-4dc9-8262-e00e9b41c36d
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 1306074
  • 1864423
  • 1306076
  • 2045502
  • 2045501
  • 1864425
  • 643193
  • 644301
  • Pharmacological Class

    • Vascular Endothelial Growth Factor Inhibitors [MoA]
    • Vascular Endothelial Growth Factor Inhibitor [EPC]

    Medicade Reported Pricing

    50242082802 XOFLUZA 20 MG TAB (40 MG DOSE)

    Pricing Unit: EA | Drug Type:

    NDC Crossover Matching brand name "LUCENTIS" or generic name "Ranibizumab"

    NDCBrand NameGeneric Name
    50242-080LUCENTISRANIBIZUMAB
    50242-082LUCENTISRANIBIZUMAB
    64406-019Byoovizranibizumab
    50242-078SusvimoRanibizumab

    Trademark Results [LUCENTIS]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    LUCENTIS
    LUCENTIS
    98765698 not registered Live/Pending
    Jun Luo
    2024-09-23
    LUCENTIS
    LUCENTIS
    78238446 3169327 Live/Registered
    GENENTECH, INC.
    2003-04-16

    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.